Latest Conference Articles

Patients with non‒small cell lung cancer whose circulating tumor MET Exon 14 is undetectable following treatment with savolitinb are more likely to have positive outcomes.

Seribantumab demonstrated efficacy in reducing tumor growth in preclinical models of NRG1 fusion–positive gastrointestinal cancers, suggesting that the use of seribantumab as monotherapy could have clinical utility in treating patients with GI and other NRG1 fusion–driven cancers.

Single-agent pembrolizumab yielded robust antitumor activity in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma.

Selpercatinib demonstrated a favorable safety profile, characterized by low-grade treatment-emergent adverse effects, manageable early onset toxicity, and low rates of treatment discontinuation, in patients with RET-altered advanced solid tumors.

Treatment with TAS-117, a highly potent and selective oral allosteric pan-v-akt murine thymoma viral oncogene homolog inhibitor, demonstrated some clinical efficacy in patients with ovarian cancer harboring PIK3CA E545K mutations and in those with breast cancer harboring PIK3CA H1047R and Akt1E17K mutations.

The tumor-infiltrating lymphocyte therapy lifileucel was found to elicit durable responses in patients with advanced melanoma who were previously treated with an immune checkpoint inhibitor.

The addition of ipilimumab to nivolumab as an adjuvant treatment failed to improve relapse-free survival in the intent-to-treat and PD-L1 of less than 1% populations compared with nivolumab alone in patients with resected stage IIIB to D/IV melanoma.

Nivolumab plus ipilimumab was found to induce significant antitumor activity when administered to patients with metastatic castration-resistant prostate cancer and immunogenic signature.

Nivolumab in combination with paclitaxel showed clinical activity and a manageable safety profile when used as second-line therapy for patients with Epstein-Barr virus–related, microsatellite instability–high/mismatch repair deficient or PD-L1–positive advanced gastric cancer.

Zenocutuzumab has been shown to block the growth and cause the death of NRG1 fusion–positive cell lines, and to induce tumor shrinkage and durable tumor regression in multiple cancers when used in NRG1 fusion–positive patient-derived xenografts.

Trastuzumab deruxtecan has not only demonstrated efficacy as a potential anti-HER2 therapeutic option for patients with HER2-amplified gastric cancers, but has also shown promise in those with HER2 moderate-, low-, and non-expressing disease.

Abdulraheem Yacoub, MD, discusses the rationale behind examining parsaclisib following suboptimal response to ruxolitinib in patients with myelofibrosis.

Xiuning Le, MD, PhD, discusses the safety findings of the phase 2 ZENITH20-5 study with poziotinib in patients with EGFR- or HER2 exon 20–positive non–small cell lung cancer.

Benjamin Besse, MD, discusses the results of an ad-hoc safety analysis of the phase 1/2 LIBRETTO-001 trial, which examined the use of selpercatinib in patients with RET-altered advanced medullary thyroid cancer and non–small cell lung cancer.

Paz Polak, PhD, discusses research that evaluated cancer genomes in Ghana through the use of liquid biopsies.

Thomas Urban Marron, MD, PhD, discusses primary objectives of a study examining the use of an adjuvant personalized neoantigen peptide vaccine in several malignancies.

The combination of copanlisib and rituximab was associated with a 48% reduction in the risk of disease progression or death compared with rituximab plus placebo in patients with relapsed indolent non-Hodgkin lymphoma.

Maintaining a healthy lifestyle was found to reduce the likelihood of developing metastatic disease or dying of prostate cancer among men who had a high genetic risk.

The presence of pathogenic or likely pathogenic germline variants in cancer predisposition genes, which were identified in approximately 1 in 5 patients with neuroblastoma and were mostly inherited, was shown to correlate with worse event-free survival and overall survival vs the absence of germline variants.

The CDK9 inhibitor voruciclib demonstrated early activity as a single agent in KRAS-mutant cancer cell lines, and synergistically inhibited growth of KRAS-mutant cancers when used in combination with sotorasib and adagrasib in preclinical models.

Tebentafusp (IMCgp100) resulted in a highly significant and clinically meaningful improvement in overall survival when given as a frontline treatment in patients with metastatic uveal melanoma.

Neoadjuvant treatment with nivolumab combined with chemotherapy led to a significant improvement in pathologic complete response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.

Faculty from the Miami Breast Cancer Conference® discuss how to apply the RxPONDER data to clinical practice.

Axel Grothey, MD, discusses the differences between available assays evaluating circulating tumor DNA in colorectal cancer.

The combination of mirvetuximab soravtansine and rucaparib was found to be well tolerated, with encouraging activity reported in heavily pretreated patients with endometrial, ovarian, fallopian tube, or primary peritoneal cancer.

A regimen comprised of a single 300-mg priming dose of tremelimumab and 1500 mg of durvalumab every 4 weeks yielded favorable efficacy and an acceptable safety profile in patients with advanced HCC.

Suresh S. Ramalingam, MD, FASCO, deputy director, director, Lung Cancer Program, Winship Cancer Institute of Emory University, professor, assistant dean, Roberto C. Goizueta Distinguished Chair for Cancer Research, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine, discusses treatment after osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC).

More patients with stage III non–small cell lung cancer received sequential chemoradiation and delayed the time to durvalumab treatment in a real-world setting compared with those enrolled on the phase 3 PACIFIC trial.

Osimertinib (Tagrisso) showcased encouraging efficacy and acceptable safety in patients with EGFR-positive, advanced non–small cell lung cancer. according to real-world findings from an observational, multicenter study.

Although the combination of atezolizumab and bevacizumab has become the standard frontline treatment for patients with advanced hepatocellular carcinoma, whether immunotherapy could play a role in earlier lines of treatment remains the subject of ongoing research.